Candida species colonization and candidiasis were examined among 868 human immunodeficiency virus (HIV)-seropositive and 437 at-risk HIV-seronegative women monitored prospectively during 1993-1999. Colonization and candidiasis acquisition rates, both oral and vaginal, were significantly higher among HIV-seropositive women; the magnitude of increase in candidiasis outcomes for HIV-seropositive women was greater for oral candidiasis than for vaginal candidiasis. Loss rates and estimates of duration of incident outcomes indicated that persistent mucosal colonization was more likely among HIV-seropositive women. However, results did not suggest persistent mucosal candidiasis. Higher HIV loads were significantly associated with increased odds of incident or persistent oral and vaginal colonization and candidiasis, an effect significantly reduced by highly active antiretroviral therapy for the incident outcomes of oral candidiasis and vaginal colonization. Cell-mediated immunodeficiency (CD4 + lymphocyte count !500 cells/mm 3 ) was significantly associated with increased odds of oral colonization or candidiasis, but not with vaginal colonization or candidiasis. In HIV-seropositive women, mucosal candidiasis is the consequence of multiple interacting factors.
immunodeficiency [5] [6] [7] [8] , but differences in frequency of colonization and patterns of mucosal disease suggest variation in the pathogenesis of candidiasis at these mucosal sites [7, 9] . Oral candidiasis has long been considered to be a sentinel clinical indicator of HIV disease progression [10, 11] . Esophageal candidiasis is a clinical AIDS-defining condition and is associated with dysphagia and wasting [12] . Vaginal candidiasis is a common condition among women of reproductive age, regardless of HIV serostatus, and its occurrence may be less related to cellular immunodeficiency [13] . Use of antifungal agents, especially the azole class, is widespread for the treatment of mucosal candidiasis. However, long-term use may lead to colonization with less susceptible Candida species or to the development of resistance among usually susceptible Candida albicans strains and, ultimately, to refractory candidiasis [8, 14, 15] . Mucosal candidiasis contributes to morbidity and reduced quality of life in patients with HIV and to the increasing medical costs for treating HIV.
Multiple behavioral and biological risk factors that may predispose persons to become colonized with Candida species and to subsequently develop mucosal candidiasis have been studied [7, [16] [17] [18] [19] [20] . For example, it is known that the risk of oral candidiasis is higher among tobacco users [18, 20] , and a higher risk for vaginal candidiasis has been found among women who are sexually active, pregnant, have diabetes, using oral contraceptives, or using antibiotics [17, 19] . Furthermore, the association of cell-mediated immunodeficiency with increased risk for mucosal Candida species colonization and candidiasis has been established, as described elsewhere [5] [6] [7] [8] . However, the role of HIV load in increasing risk and the corresponding potential beneficial role of highly active antiretroviral therapy (HAART) in reducing risk have not been adequately studied [21] .
Although Candida species colonization and candidiasis are frequently seen in clinical practice and prevalence estimates have been reported in the literature, few data are available regarding the acquisition or loss rates, as well as the duration of these conditions, and whether rates differ by HIV serostatus. In the present study, we report findings from the HIV Epidemiology Research Study (HERS), a multicenter, longitudinal cohort study of US women living with or at-risk for HIV infection. HERS was designed to study the biological, behavioral, and social determinants of HIV disease progression [22] . Our objectives in the present study were to examine the dynamics of oropharyngeal and vaginal Candida species colonization and candidiasis among HIV-seropositive and HIV-seronegative women monitored prospectively during 1993-1999. Specifically, we estimated and compared acquisition and loss rates and duration of oropharyngeal and vaginal Candida species colonization and candidiasis, by HIV serostatus. We also evaluated the associations of demographic characteristics, HIV serostatus/CD4 + lymphocyte category, risk behaviors, medication use, and HIV load with incident (moving from negative to positive) or persistent (remaining positive) outcomes between consecutive visits over time.
SUBJECTS AND METHODS
Participants and participant characteristics. From April 1993 through January 1995, 871 HIV-seropositive and 439 demographically and behaviorally similar HIV-seronegative women were enrolled at HERS sites in Bronx (NY), Detroit (MI), Baltimore (MD), and Providence, (RI). Institutional review boards at participating institutions approved the present study, and all participants provided informed consent. Details of the HERS design and selection of participants have been published elsewhere [22] . Women aged 16-55 years were eligible for participation if they reported high-risk sexual behavior or injection drug use (since 1985), agreed to HIV counseling and testing, and, if HIV seropositive, reported no history of clinical AIDSdefining conditions. By design, each study site contributed equivalent numbers of participants, and enrollment risk behaviors were equally distributed by HIV serostatus; HIV-seropositive and HIVseronegative women were enrolled at a 2:1 ratio. Women were interviewed and received targeted physical examinations at baseline and at each semiannual follow-up visit. Study visits were scheduled in advance and were not symptom driven. Data collected during interviews included information on sociodemographics, medical history (including use of medications), and risk behaviors (including substance use).
Oral and gynecologic examinations were performed by study clinicians trained in the diagnosis of oropharyngeal and genital tract conditions. Specimens for fungal culture from the oropharynx and vagina were collected by swab and were processed to identify those women colonized with Candida species. Mucosal Candida species colonization was defined as the presence of organisms, as determined by culture on Sabouraud dextrose agar incubated at 30ЊC. Oral candidiasis was defined as oral Candida species colonization plus clinical signs of pseudomembranous, erythematous, or both types of oral lesions. Vaginal candidiasis was defined as vaginal Candida species colonization, plus examiner-determined abnormal vaginal discharge, and either vaginal erythema or edema.
At each visit, blood samples were collected for immunophenotyping by flow cytometry and determination of HIV load (plasma RNA levels). We categorized CD4 + lymphocyte counts as !200, 200-500, and 1500 cells/mm 3 . Determination of HIV load (copies/mL) was performed by use of a bDNA signal amplification assay (Chiron). HIV loads were categorized as !50 copies/mL (below detectable limits of assay), 50-1000 copies/ mL, 1001-10,000 copies/mL, 10,001-30,000 copies/mL, and 130,000 copies/mL. We also log transformed HIV loads for improved symmetry and included them in models as continuous values. Values below detectable limits were coded as onehalf of the detectable value before being log transformed.
By using data from medical record abstractions, we determined the current clinical AIDS status for HIV-seropositive women at each visit after baseline. Abstractions were initiated by study participants' affirmative responses to queries regarding hospitalizations or diagnostic procedures since the last study visit. Twenty-four specified clinical conditions were included in the clinical AIDS definition on the basis of the Centers for Disease Control and Prevention 1993 classification system [12] . Esophageal candidiasis was considered among these AIDS-defining conditions; women diagnosed with this condition during follow-up were identified. Demographic variables considered in analyses included age, race/ethnicity, and education. At each visit, women who reported sexual activity with у1 partners, pregnant women, and women who reported recent (last 6 months) tobacco or injection drug use were identified. Women using antifungal therapies (both systemic and topical), antibiotic therapies (including those used for treatment and prophylaxis of opportunistic infections), or medications to manage diabetes also were identified. HIV-seropositive women who reported receiving any antiretroviral therapy (ART) including HAART, as defined by Department of Health and Human services guidelines [23] , were identified at each visit; reported ART was categorized as either HAART or sub-HAART (i.e., non-HAART combination therapy or monotherapy), compared with no ART.
Study objectives and statistical analyses Statistical analyses were performed using SAS statistical software (version 6.12; SAS Institute). We examined baseline population characteristics, including prevalence of oral and vaginal Candida species colonization and candidiasis by HIV serostatus, using x 2 test for categorical variables and Wilcoxon rank-sum test for continuous values [7] . Acquisition of oral or vaginal Candida species colonization or candidiasis during follow-up (hazard rates expressed as no. of cases/100 person-years observation), rates for loss of condition among those with incident conditions, and rate ratios for HIV-seropositive versus HIV-seronegative women were estimated by use of exponential survival models. Both oral and vaginal Candida species colonization were highly prevalent at baseline, and patterns of colonization, clearance, and recolonization (rather than continuous colonization or colonization with permanent clearance) were suspected to occur frequently. We included participants with baseline colonization or candidiasis in incidence evaluations if they returned to negative status during follow-up; observation time considered in rate estimates included only that time (consecutive visits) while negative prior to first incident outcome or censor (i.e., loss to follow-up or end of study). Similarly, participants considered in rate estimates for loss of condition included all participants with incident colonization or candidiasis, regardless of baseline status; observation time included consecutive visits while positive prior to first incident loss of outcome or censor. Estimates of duration of specified conditions among those with incident outcomes were estimated by use of the Kaplan-Meier method, with evaluations of differences in survivor functions (probability of continued colonization or candidiasis versus loss of colonization or candidiasis) by HIV serostatus. Finally, cumulative prevalences (prevalence at у1 visits, including at baseline) of oral and vaginal Candida species colonization and candidiasis by HIV serostatus were estimated.
We estimated odds of incident (moving from negative to positive) or persistent (remaining positive) oral or vaginal Candida species colonization or candidiasis (compared with loss [moving from positive to negative] or remaining negative) between consecutive visit-pairs over time and factors associated with these outcomes by use of repeated measures multivariate logistic regression. These models assumed appropriate correlation structures to account for within-subject correlation across multiple observations on the same subject [24] . Covariates considered in these models were permitted to have different values at each visit and were modeled as status at time of the follow-up visit of a visit-pair or as lag variables, with status at time of the initial visit of a visit-pair considered. Multivariate models considered the associations of HIV serostatus/CD4 + lymphocyte category, risk behaviors, medications, including ART (HAART/sub-HAART), HIV load (categorical or logtransformed continuous values), clinical AIDS diagnoses, and other covariates related to the outcomes in preliminary analyses. These models were adjusted for time (visit), study site, participant demographic characteristics, and colonization or candidiasis status at initial visit of visit pairs. In addition to these full models that examined the independent effects of these factors on outcomes, reduced models were run and, limited data were presented to evaluate the effect of treatment with HAART on outcomes without adjustment for virus load. We further evaluated the relative contribution of HIV-specific variables, including CD4 + lymphocyte category, HIV load, and ART, to odds of specified conditions by considering results of type-3 contrasts. These contrasts generated estimates of the magnitude of effect of multilevel categorical variables on the outcome, which was conditional on all other covariates considered in models.
RESULTS
Candida species colonization and candidiasis data were available from 1305 women (5 participants in the HERS did not contribute any data to these analyses) for up to 12 visits (5.5 years of observation). The data included results from 10,492 oral and 10,331 gynecologic examinations with Candida culture. Ninety-one percent of participants provided follow-up data, and 76% of participants provided data from at least 5 study visits. Median follow-up was 4 years and did not differ by HIV serostatus. Baseline characteristics of the 868 HIVseropositive and 437 HIV-seronegative women who contributed data to these analyses are presented in table 1. HIV-seropositive women were significantly more likely than were HIV-seronegative women to have oral colonization, oral candidiasis, or vaginal colonization identified at baseline; prevalence of vaginal candidiasis, although higher among HIV-seropositive women, did not significantly differ by HIV serostatus [7] .
Oral Candida species colonization. The rate of acquisition of oral Candida species colonization was significantly higher among HIV-seropositive women than among HIV-seronegative women, and the rate of loss of colonization was significantly lower (table 2) . One-year after incident colonization (2 followup study visits), a higher proportion of HIV-seropositive women than HIV-seronegative women remained colonized. Over the course of 5.5 years of observation (up to 12 semiannual study visits), more HIV-seropositive women than HIV-seronegative women had у1 visits, at which time oral Candida species colonization was identified.
Analyses of factors associated with odds of incident or persistent oral Candida species colonization among HIV-seropositive and HIV-seronegative women indicated that HIV-seropositive women with CD4 + lymphocyte counts !500 cells/mm 3 had increased odds of oral colonization; the greatest odds were among those who had the lowest CD4 + lymphocyte count (table  3) . Women who reported using tobacco, injection drugs, antibiotics, or medications to manage diabetes had increased odds of oral colonization, whereas those who reported using antifungals had decreased odds. Among HIV-seropositive women, odds of oral colonization were significantly increased among those with HIV load values 110,000 copies/mL. Similarly, odds increased 6%-7% ( ) for every log 10 increase in HIV P ! .001 load (e.g., HIV load between 1000 copies/mL and 10,000 copies/ mL) when we considered log-transformed continuous values ) was not associated with P p .83 reduced odds of oral colonization when values for HIV load were excluded from the model. "Lag" variables indicate status at time of the initial visit of a visit pair. ART, antiretroviral therapy; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; OR, odds ratio; Sub-HAART, non-HAART combination therapy or monotherapy.
representing status at initial or follow-up visits of visit pairs. Use of HAART was not significantly associated with reduced odds of oral colonization, regardless of whether values for HIV load were included in the model. Current clinical AIDS status was unrelated to odds of oral colonization. We adjusted this model for oral colonization status at the initial visit of visit pairs; results indicated that odds of persistent colonization were greater than odds of incident colonization.
Oral candidiasis. The rate of acquisition of oral candidiasis was higher among HIV-seropositive women than among HIVseronegative women (table 2) . Although the rate of loss of candidiasis was one-third lower among HIV-seropositive women, the difference was not significant by HIV serostatus. Oral candidiasis persisted for at least 1 additional study visit in 33% of HIV-seropositive women but not in HIV-seronegative women. Over the course of up to 12 semiannual study visits, more HIVseropositive women than HIV-seronegative women had у1 visits with oral candidiasis identified.
Analyses of factors associated with incident or persistent oral candidiasis among HIV-seropositive and HIV-seronegative women were examined (table 4). The odds of oral candidiasis were increased 7-fold for HIV-seropositive women with CD4 + lymphocyte counts !200 cells/mm 3 , compared with that in HIVseronegative women. The odds were increased 12-fold among tobacco users. For HIV-seropositive women, odds of oral candidiasis increased 2-5-fold as HIV load values increased from nondetectable values (!50 copies/mL); similarly, odds increased 17%-26% for every log 10 increase in HIV load measured as log-transformed continuous values at initial or follow-up visits. ) when values for HIV load were excluded P p .015 from the model; current clinical AIDS status was not significantly related to the outcome. The odds of persistent oral candidiasis were greater than the odds of incident candidiasis.
Vaginal Candida species colonization. The rate of acquisition of vaginal Candida species colonization was significantly higher among HIV-seropositive women than HIV-seronegative women, and the rate of loss of colonization was significantly lower (table 2) . One-year after incident colonization (2 followup study visits), a higher proportion of HIV-seropositive women than HIV-seronegative women remained colonized. Over the course of up to 12 semiannual study visits, more HIV-seropositive women than HIV-seronegative women had у1 visits with vaginal Candida species colonization identified.
Results from analyses of factors associated with odds of incident or persistent vaginal Candida species colonization among HIV-seropositive and HIV-seronegative women indicated several significant associations (table 5) . Pregnant women, women who reported using antibiotics, or women using medications to manage diabetes had increased odds of vaginal colonization; women who reported using antifungals had decreased odds. Among HIVseropositive women, the odds of vaginal colonization were increased 43%-59% for women whose HIV load was 11000 copies/ mL; similarly odds increased 5%-6% for every log 10 increase in HIV load measured as log-transformed continuous values at initial or follow-up visits. Immunodeficiency (CD4 + lymphocyte ) when HIV load was excluded from P p .013 the model. This model was adjusted for vaginal colonization status at the initial visit of visit pairs; results indicated that the odds of persistent colonization were greater than the odds of incident colonization.
Vaginal candidiasis. The rate of acquisition of vaginal candidiasis was significantly higher among HIV-seropositive women than among HIV-seronegative women, whereas the rate of loss of candidiasis was similar (table 2) . Most cases (81%) among HIV-seronegative women were present for only the incident visit; among HIV-seropositive women, 74% of cases resolved after the incident visit and an additional 24% resolved after being present for 2 consecutive visits. Over the course of up to 12 semiannual study visits, more HIV-seropositive women than HIV-seronegative women had у1 visits with vaginal candidiasis identified.
Analyses of factors associated with incident or persistent vaginal candidiasis among HIV-seropositive and HIV-seronegative women were examined (table 6). Pregnant women and women who reported using medications to manage diabetes had increased odds of vaginal candidiasis. Among HIV-seropositive women, odds of vaginal candidiasis increased 12-fold for women whose HIV load was 11000 copies/mL; similarly, odds increased 11%-14% for every log 10 increase in HIV load measured as log-transformed continuous values at initial or followup visits. Level of immunodeficiency, as measured by CD4 + lymphocyte category, was not significantly related to increased odds after adjustment for HIV load. Use of HAART was not significantly associated with reduced odds of vaginal candidiasis, regardless of whether HIV load was included in the model; current clinical AIDS status was unrelated to the outcome. Odds of persistent vaginal candidiasis were greater than odds of incident candidiasis.
DISCUSSION
We analyzed the dynamics of mucosal Candida species colonization and candidiasis among a large cohort of HIV-seropositive and demographically and behaviorally similar HIVseronegative women followed prospectively for a median of 4 years. Acquisition rates for oral and vaginal Candida species colonization were significantly higher in HIV-seropositive women than in HIV-seronegative women; rates were 140% higher for oral colonization than for vaginal colonization in both cohorts. Persistent colonization at either mucosal site was significantly more likely among HIV-seropositive women than among HIV-seronegative women, and duration of oral colonization was greater than duration of vaginal colonization in both cohorts. Ninety percent of HIV-seropositive women and 83% of HIV-seronegative women were orally colonized with Candida at least once during the course of the study. Similarly, 83% of HIV-seropositive women and 71% of HIV-seronegative women were vaginally colonized at some time. The implication is that most women become colonized at least transiently.
Acquisition rates for oral and vaginal candidiasis were sig- 
NOTE.
Model adjusted for study site and time (visit). In separate models, log 10 HIV load at initial (OR, 1.05; 95% CI, 1.02-1.08;
) and follow-up P ! .001 (OR, 1.06; 95% CI, 1.03-1.09; ) visits of visit-pairs were significantly P ! .001 associated with increased odds of incident or persistent vaginal colonization; HAART use (OR, 0.76: 95% CI, 0.62-0.95; ) was significantly P p .013 associated with reduced odds of vaginal colonization when values for HIV load were excluded from the model. "Lag" variables indicate status at time of the initial visit of a visit pair. ART, antiretroviral therapy; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus: OR, odds ratio; Sub-HAART, non-HAART combination therapy or monotherapy.
nificantly higher in HIV-seropositive women than in HIV-seronegative women; however, differential acquisition rates by mucosal site existed within each cohort. Among HIV-seropositive women, the rate of acquisition was 1.5 times higher for oral candidiasis than for vaginal candidiasis; among HIV-seronegative women, the rate was 4 times higher for vaginal candidiasis than for oral candidiasis. Thus, vaginal candidiasis was more common than oral candidiasis in HIV-seronegative women, as expected. In HIV-seropositive women, vaginal candidiasis showed less of an increase in frequency than did oral candidiasis as a result of HIV infection. Estimates of rates for loss of incident candidiasis and duration of candidiasis did not suggest differences in persistence of candidiasis by HIV serostatus, at least for vaginal candidiasis. These findings support our hypothesis of differences in pathogenesis of candidiasis at these 2 mucosal sites.
In the present study, demonstrated associations of participant demographic characteristics, behaviors (tobacco use), and medical status (pregnancy or diabetes) with likelihood of incident orpersistent colonization or candidiasis outcomes were consistent with results from previous studies, as described elsewhere [7, 8, [16] [17] [18] [19] [20] . The odds of both oral and vaginal colonization were increased among participants who reported use of antibiotics and decreased among participants who reported use of antifungals, which was expected. However, use of antibiotics and antifungals were not significantly related to likelihood of oral or vaginal candidiasis, perhaps because the study design did not permit capture of incident episodes of symptomatic oral and vaginal candidiasis occurring between scheduled visits. Candidiasis as defined may have reflected predominately asymptomatic disease.
Our finding of significantly increased risk of oral Candida species colonization and candidiasis in HIV-seropositive women with progressive immunodeficiency is consistent with baseline data and numerous clinical observations [5-8, 10, 11] . In contrast, we did not demonstrate a significant correlation between CD4 + lymphocyte count and vaginal colonization and disease. The occurrence of vaginal colonization and candidiasis has been linked specifically to sexual, hormonal, and behavioral factors [17, 19] and may be less related to cellular immunodeficiency [13] . In addition, the vagina has been identified as a compartmentalized site, distinctly or partially sequestered from systemic cell-mediated immunity, with unique innate defense mechanisms and subpopulations of lymphocytes [25] . These local mucosal immune mechanisms may operate independently of systemic cell-mediated immunity.
An independent role for HIV load in influencing the odds of colonization and candidiasis is suggested, because higher HIV loads were significantly associated with increased odds of incident or persistent, oral and vaginal colonization and candidiasis. Results of type-3 contrasts, conducted using data from HIV-seropositive women only (data not shown), indicated that the relative contribution of immunodeficiency (CD4 + lymphocyte count) and HIV load to oral colonization were nearly identical, whereas, for oral candidiasis, the magnitude of effect was greater for immunodeficiency than for HIV load. In contrast, for vaginal colonization, the relative contribution of HIV load was greater than that of immunodeficiency; for vaginal candidiasis, the magnitude of effect was greater for HIV load without a significant effect for immunodeficiency. The independent role of HIV per se to the process of colonization and, especially, candidiasis at both mucosal sites has not previously been shown in large cohort studies. Previously, HIV disease was considered to predispose individuals to opportunistic infection indirectly by virtue of reduced cell-mediated immune mechanisms. In a small cross-sectional study of oropharyngeal Candida species colonization in 83 individuals with HIV-1 infection, however, Gottfredsson et al. [26] reported that only plasma HIV-1 load was predictive of Candida load; neither CD4 + lymphocyte level nor use of ART was associated with colonization. Gottfredsson et al. [26] hypothesized that high levels of HIV-1 may suppress local mucosal immune mechanisms independently of systemic cell-mediated immunity, thereby permitting increased Candida species colonization, and further speculated that control of HIV replication may restore local immune function. In addition, Gruber et al. [27] , on the basis of in vitro observations, proposed that high plasma and hence salivary/oral HIV load, specifically HIV-1 glycoproteins, might promote virulence of C. albicans.
Clinical AIDS status was not significantly related to incident or persistent Candida species colonization or candidiasis in multivariate models. In addition, esophageal candidiasis, an AIDSdefining condition, was noted infrequently in women during the study period (data not shown). Esophageal candidiasis may be empirically diagnosed and treated on an outpatient basis. We had limited ability to capture these events, because only outcomes associated with hospitalizations or specified procedures (endoscopy) were considered in our definitions.
Our findings suggested that use of HAART was consistent with reduced odds of oral candidiasis and vaginal colonization outcomes, when values for HIV load were excluded from respective models. This association supports the frequent clinical observation of dramatically reduced oral candidiasis in patients receiving HAART [28] . In contrast, HAART was not associated with reduced likelihood of oral colonization or vaginal candidiasis. Failure to demonstrate reduced odds of vaginal candidasis with HAART use once again suggests different pathogenic mechanisms at each mucosal site. Our observations indirectly suggest that the beneficial effect of HAART is not entirely dependent on enhanced mucosal immunity but on achieving decreased virus load. It is also possible that protective immune function at the mucosa may reflect mechanisms other than T lymphocyte cell function.
Our study cohort included an ethnically diverse population of adult women of wide-ranging ages representing both injection drug use and high-risk sexual contact HIV risk behaviors. Outcomes were based on results of laboratory studies and identification of clinical signs, carried out at nonsymptom-driven study visits scheduled approximately every 6 months. Because outcomes could have occurred between visits, estimates associated with acquisition, loss, and duration may not reflect the actual number of new or continuing cases. Our definitions of candidiasis outcomes, especially vaginal candidiasis, are limited, because they do not consider evidence of symptomatic disease.
Other analyses of HERS data have examined vaginal candidiasis using 3 definitions of varying stringency with corresponding variation in frequency estimates [29] . Our definition was more stringent than these; however, results were reasonably consistent between the analyses and led to similar conclusions.
In the present study, Candida species colonization rates in the oropharynx and vagina were high in HIV-seropositive women. Over time, oral candidasis was not only more common but different than vaginal candidiasis. Our results emphasize that colonization and candidiasis are the consequences of interacting host, viral, and yeast influences on the pathogenesis of these syndromes. The differences demonstrated strongly suggest that pathogenic mechanisms are different at these two mucosal sites. It has been customary to see opportunistic infections only in light of systemic immunodeficiency; however, our data suggest an effect of HIV load independent of CD4 + lymphocyte count, as has been previously reported with hepatitis C virus [30] . It is possible that HIV has a direct effect on the pathogenicity of opportunistic organisms or an indirect effect, such as by affecting local immune function.
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